Enliven Therapeutics, Inc. $ELVN Stock: Candriam S.C.A. Decreases Stake

Candriam S.C.A. trimmed its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 6.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 846,451 shares of the company’s stock after selling 59,223 shares during the period. Candriam S.C.A. owned 1.16% of Enliven Therapeutics worth $38,943,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Pictet Asset Management Holding SA increased its stake in Enliven Therapeutics by 14.1% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,325,740 shares of the company’s stock worth $60,772,000 after buying an additional 163,956 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Enliven Therapeutics in the third quarter valued at about $172,000. Profund Advisors LLC boosted its stake in shares of Enliven Therapeutics by 260.8% in the third quarter. Profund Advisors LLC now owns 27,874 shares of the company’s stock worth $1,278,000 after acquiring an additional 20,148 shares during the period. ProShare Advisors LLC boosted its stake in shares of Enliven Therapeutics by 29.5% in the third quarter. ProShare Advisors LLC now owns 9,852 shares of the company’s stock worth $452,000 after acquiring an additional 2,246 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Enliven Therapeutics by 37.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,369 shares of the company’s stock worth $622,000 after acquiring an additional 3,676 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Up 10.4%

Enliven Therapeutics stock opened at $49.43 on Friday. The company has a market cap of $3.62 billion, a price-to-earnings ratio of -28.91 and a beta of 0.34. The firm’s fifty day moving average is $47.25 and its 200 day moving average is $43.08. Enliven Therapeutics, Inc. has a 52-week low of $14.78 and a 52-week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. On average, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director J. Scott Garland sold 13,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director directly owned 13,000 shares in the company, valued at approximately $606,710. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the sale, the chief financial officer directly owned 38,000 shares in the company, valued at $1,462,240. This trade represents a 13.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 31,054 shares of company stock worth $1,493,823. Company insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

ELVN has been the topic of several research analyst reports. JPMorgan Chase & Co. began coverage on shares of Enliven Therapeutics in a report on Thursday, October 1st. They issued an “overweight” rating and a $75.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and set a $78.00 target price on shares of Enliven Therapeutics in a research note on Friday. Morgan Stanley initiated coverage on shares of Enliven Therapeutics in a report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price target on the stock. Zacks Research cut shares of Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 13th. Finally, HC Wainwright increased their price target on Enliven Therapeutics from $65.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Ten investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.44.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.